Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.37 Bn | 2.31 Bn | 151.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.25% |
| Dec 31, 2025 | 54.71% |
| Sep 30, 2025 | 25.30% |
| Jun 30, 2025 | 27.20% |
| Mar 31, 2025 | -3.40% |
| Dec 31, 2024 | 12.98% |
| Sep 30, 2024 | 18.11% |
| Jun 30, 2024 | 43.85% |
| Mar 31, 2024 | -14.74% |
| Dec 31, 2023 | 17.95% |
| Sep 30, 2023 | 10.70% |
| Jun 30, 2023 | -6.25% |
| Mar 31, 2023 | -19.31% |
| Dec 31, 2022 | -17.79% |
| Sep 30, 2022 | -21.15% |
| Jun 30, 2022 | -23.49% |
| Mar 31, 2022 | -55.61% |
| Dec 31, 2021 | -40.86% |
| Sep 30, 2021 | -5.80% |
| Jun 30, 2021 | -17.84% |